|BIND Therapeutics, Inc.|
325 Vassar Street
United States - Map
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The companys lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
|Mr. Scott L. Minick ,
Chief Exec. Officer, Pres and Director
|Dr. Robert S. Langer Jr., Ph.D., Sc.D,
Co-Founder, Chairman of Scientific Advisory Board, Consultant, Director and Member of Nominating & Corp. Governance Committee
|Dr. Jeff Hrkach Ph.D.,
Chief Technology Officer
|Dr. Gregory I. Berk M.D.,
|Mr. Andrew Hirsch ,
Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|